Gsk (GSK) Current Deferred Revenue (2016 - 2018)

Gsk (GSK) has 3 years of Current Deferred Revenue data on file, last reported at $277.9 million in Q4 2018.

• In Q4 2018, Current Deferred Revenue fell 12.77% year-over-year to $277.9 million; the TTM figure through Dec 2018 stood at $277.9 million (down 12.77% YoY), while the FY2018 annual figure was $288.5 million, down 6.69% from the prior year.
• Current Deferred Revenue fell to $277.9 million in Q4 2018, from $318.6 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $318.6 million in Q4 2017 and bottomed at $196.4 million in Q4 2016.
• A 3-year average of $264.3 million and a median of $277.9 million in 2018 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2017 — Current Deferred Revenue surged 62.22% — and 2018, when it fell 12.77%.
• Year by year, Current Deferred Revenue stood at $196.4 million in 2016, then jumped by 62.22% to $318.6 million in 2017, then retreated by 12.77% to $277.9 million in 2018.
• The last three Current Deferred Revenue figures came in at $277.9 million (Q4 2018), $318.6 million (Q4 2017), and $196.4 million (Q4 2016), per Business Quant data.

Peer Comparison